Physician profile
Obaid U Awan
NPI 1831385780
$2,202.39
in general payments reported to CMS, 2019-2025
22 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $358 · 2021: $197 · 2022: $324 · 2023: $343 · 2024: $436 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $638.90 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Glaxosmithkline, LLC. | $536.23 | 2019-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $243.18 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $208.85 | 2020-2025 | Andexxa, Airsupra |
| Pfizer INC. | $74.74 | 2021-2022 | |
| Abbvie INC. | $70.25 | 2021-2025 | Avycaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.71 | 2020-2023 | Ofev |
| Merck Sharp & Dohme LLC | $43.71 | 2024 | Keytruda, Zerbaxa |
| Genentech USA, INC. | $42.05 | 2020 | |
| Genzyme Corporation | $41.95 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $38.64 | 2025 | Purified Cortrophin Gel |
| La Jolla Pharmaceutical Company | $28.62 | 2020 | |
| Pinnacle Biologics, INC | $25.88 | 2024 | Photofrin |
| Portola Pharmaceuticals, LLC | $22.16 | 2019 | |
| Mylan Specialty L.P. | $19.95 | 2024 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.48 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.11 | 2022 | |
| Insmed, INC. | $17.47 | 2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $17.06 | 2024 | Glassia |
| Sandoz INC. | $16.09 | 2023 | Treprostinil |
| Inspire Medical Systems, INC. | $15.17 | 2024 | Inspire |
| Sunovion Pharmaceuticals INC. | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obaid Awan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.